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Before marketing a cosmetic product, a series of biological assays, such as ocular irritation tests, must 
be conducted in order to prove that the product is safe. However, a few scientific articles mention the 
discussion and evolution of cosmetic products testing performed in the eyes area. The aim of this study 
was to review the available literature on the evolution of tests carried out with cosmetics, in the ocular 
area, as well as to describe the methodologies that have been used and that are currently accepted. In 
Brazil, tests performed on animals are still allowed. However, the international laws strongly recommend 
the use of alternative methods for evaluating the risk of cosmetic ingredients and products. Regulatory 
requirements involving the registration of these products also request safety support of them in human 
beings. To perform ocular tests in human beings, it is necessary to involve an ophthalmologist for 
conducting clinical protocols. These protocols signed by the expert physician are sent to the National 
Health Surveillance Agency in order to endorse the product manufacturer concerning its safety. The 
safety support of a cosmetic product is very important, taking into account that the consumer has free 
access to these products of widespread use in today’s society.
Uniterms: Eyes/cosmetics use. Cosmetics/safety assessment. Ocular irritation/tests. Ocular area/safety 
use of cosmetics
Com o objetivo de comprovar que um produto cosmético é seguro, antes que este seja colocado no 
mercado, este deve passar por uma série de ensaios biológicos, que avaliem sua segurança, como, por 
exemplo, os testes de irritação ocular. Porém, poucos artigos científicos trazem a discussão e a evolução 
sobre os testes de produtos cosméticos realizados na área dos olhos. O objetivo desse trabalho foi realizar 
uma revisão bibliográfica sobre a evolução dos testes realizados com cosméticos, na região ocular, bem 
como descrever as metodologias que já foram utilizadas e as que são aceitas atualmente. No Brasil, 
são ainda permitidos testes em animais, entretanto, as legislações internacionais indicam fortemente a 
utilização de métodos alternativos para avaliação de risco de ingredientes e produtos cosméticos. As 
exigências regulatórias que envolvem o registro desses produtos solicitam também a comprovação de 
segurança destes produtos em serem humanos. Para a realização dos testes oculares em humanos, é 
necessário o envolvimento de um oftalmologista na condução de protocolos clínicos. Esses protocolos 
assinados pelo médico especialista são enviados à Agencia Nacional de Vigilância Sanitária, a fim de 
respaldar o fabricante do produto sobre a segurança do mesmo. A comprovação da segurança de um 
produto cosmético é bastante importante, considerando-se o livre acesso aos consumidores e o amplo 
uso desses produtos na sociedade atual.
Unitermos: Olhos/uso de cosméticos. Cosméticos/segurança. Irritação ocular/testes. Região ocular/uso 
seguro de cosméticos
M. L. Cancian, M. S. Leonardi, M. M. Mosca, L. O. Guerra, S. F. Hengeltraub, G. R. Leonardi668
INTRODUCTION
The Brazilian health legislation comprises several 
regulatory rules (Laws, Decrees, Resolutions, Ordinances, 
etc.). The role of the National Health Surveillance Agency 
is to regulate, control and supervise the processes, 
products, supplies and services that can potentially 
be harmful to the population’s health. In Brazil, these 
activities received a great stimulus with the creation of 
the National Health Surveillance Agency - ANVISA 
(Lucchese, 2001).
In order to ensure the consumer is purchasing 
safe and quality products, ANVISA is responsible 
for authorizing the marketing of toiletries, cosmetic 
and fragrance products, by granting the manufacturer 
the product registration or notification. ANVISA also 
supervises and sets standards for the manufacturing 
companies, by checking the production process, the 
techniques and methods used until the final consumption. 
Thus, both the production and the marketing process of 
cosmetic products in Brazil are regulated by ANVISA and, 
therefore, subjected to its supervision.
According to the Guide for the Safety Evaluation 
of Cosmetic Products of ANVISA, cosmetics, fragrances 
and toiletries are formulations constituted by natural or 
synthetic substances for external use on several parts of 
the human body: skin, hair, nails, lips, external genital 
organs, teeth and mucous membranes of the oral cavity, 
aiming exclusively to clean, scent, change the aspect and/
or correct body odors and/or protect or keep them in good 
condition (ANVISA, 2003).
Cosmetics, as well as toiletries and fragrance 
products are classified according to the degree of risk 
they offer, in which grade 1 represents the products with 
minimal risk and grade 2 products with potential risk 
(RDC 211, 2005). The criteria for this classification were 
defined by ANVISA according to the intended product use, 
body areas covered, use directions and any special care to 
be observed during use (Leonardi, 2008).
For marketing products rated as Risk Level 1, a 
notification must be sent 30 days prior to their marketing. 
For submitting the notification, it is not necessary to 
submit studies to prove its safety and efficacy. However, 
the National Health Surveillance Agency may require 
the manufacturer to present at any time, the safety tests 
performed. Thus, it is important for the manufacturer to 
properly evaluate the safety of the product and maintain 
all study records.
Products rated as Risk Level 2 are those with specific 
recommendations, which characteristics require safety 
and/or efficacy support, as well as information and special 
care concerning the use directions and restrictions, in that 
it is mandatory to present this information when requesting 
the product registration (RDC 343, 2005).
The safety evaluation of cosmetic products before 
marketing is extremely important for preserving 
consumer’s health. The first exposure to a new cosmetic 
product must occur in a controlled and monitored way, 
in clinical studies monitored by expert physicians, and 
not in a large scale, in the consumer market. It is a way to 
prevent the occurrence of unexpected reactions directly 
to the consumers, preserving the health and wellbeing of 
the population.
Despite the existence of different processes for 
products registration and notification, the importance 
must be directed to the conduction of an appropriate safety 
evaluation of the products. Resolution No. 79 of August 
28th, 2000 updates the list of allowed, allowed with use 
restricted to certain conditions or prohibited substances 
in cosmetic products, and updates the standards and 
procedures contained in Resolution 71/96 concerning the 
registration of toiletries, cosmetic and fragrance products 
and others included in this context. Products categories 
not existing in Resolution 71/96 were also created. A 
cream for cellulite or stretch marks, for example, that 
had no specific category before, with the publication of 
Resolution 79, enters the category “cellulite/stretch marks 
cream” and is rated as a product of risk level 2. The same 
occurs with body products containing SPF that are now 
rated as products of risk level 2 (RDC 79, 2000).
As a consequence, besides using safe raw materials 
covered by the conditions outlined in the lists of substances 
made available by the Regulatory Agency, the industry 
should have the results proving the safety of every 
marketed cosmetic product.
When submitting their products for clinical trials, 
the company must ensure they do not offer foreseeable 
risks for the subjects and that the raw materials used are 
consecrated and do not represent health risk. Furthermore, 
the company should confirm that ingredients unauthorized 
by the Regulatory Agency are not used and, in the 
case of regulated ingredients, that they are not used at 
concentrations above those allowed. This information 
must be explained and evidenced through a Responsibility 
Statement issued by the sponsor.
Currently, a wide range of tests allows evaluating 
a cosmetic product regarding its safety in many different 
aspects. It is possible to evaluate the finished product or 
its raw materials.
These studies comprise non-clinical assays - in 
which raw materials or finished products are evaluated in 
animals or through in vitro methods - and clinical trials in 
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which the finished product is tested on human subjects.
In vitro non-clinical assays are important today 
for replacing the tests performed in animals, with some 
alternative methods already internationally validated. 
Initially developed to properly meet the needs of the 
pharmacology studies, alternative methods were also 
used to evaluate the toxicological effects (ANVISA, 
2012). They are of a great importance to evaluate new 
raw materials.
After running pre-clinical tests, the product safety 
when in human use should be evidenced by clinical studies 
results (ANVISA, 2012).
The clinical trials aim to confirm the safety of the 
finished product, taking into account possible interactions 
between the ingredients, which are required for products 
registration (ANVISA, 2003).
The clinical and non-clinical studies may prove 
the safety of components or finished products, by 
evaluating the potential for skin irritation, photoallergy 
and phototoxicity, ocular irritation, acnegenicity, 
comedogenicity, sensitization, among others.
The ocular irritation studies are not required for 
registration, unless the manufacturer wishes to explore 
as product claims expressions like “Ophthalmologically 
Tested” or “Tear-free”, for example. However, it is 
important to highlight that if any consumer reports any 
unwanted effect in the eyes, the manufacturer may be 
required to present tests confirming the product safety in 
this area.
Therefore, although mandatory only in cases in 
which special claims are used on the product labels, tests 
in the ocular area are extremely important, since toxic 
profile products may cause injury when in contact with the 
eyes (Azevedo, 2003), as occurred in the 30s in the United 
States with Lash Lure® cosmetics, which made at least 12 
individuals go blind. These cosmetics were used in beauty 
salons as permanent colorant for eyelashes and eyebrows. 
Its composition comprised amine paraphenylene, a 
substance with high dermal-sensitizing potential, causing, 
weeks after use, severe corneal damages to its consumers. 
(Wilhelmus, 2001; Nóbrega et al., 2008).
Non-clinical studies in animals
The non-clinical test for evaluating the ocular 
irritation potential of a compound was first described 
in 1944 by John H. Draize and his collaborators (Alves, 
2003). This test was performed on at least six albino 
rabbits of the New Zealand breed, where about 0.1mL of 
the substance at different concentrations was applied to 
one eye of the rabbit, while the other one served as control. 
Then, the eyelids were held together for a few seconds. 
There was no eyes washing, allowing only the tearing to do 
the removal. The eyes were examined after 1, 24, 48 and 
72 hours of application. If the reactions were positive, the 
evaluations continued for up to seven days. Damages to the 
cornea (opacity), iris (hyperemia, hemorrhage and edema) 
and conjunctiva (hyperemia, chemosis and secretion) were 
evaluated in the eyes of the rabbits and, for each lesion, 
a score at different degrees was assigned, according to 
the intensity of the reaction observed (Draize, Woodard, 
Calvery, 1944; McNamee, 2011).
However, the Draize test came under constant 
criticism by both those who defend the animal welfare and 
the scientific community, which questioned the variability 
of the results obtained, the subjectivity of the ocular 
damages and the overestimation of the effects in humans 
by using high doses of the product. These criticisms led 
to the search for alternative procedures that aimed to 
reduce the number of animals used or to develop studies 
for replacing testing in animals (Costa, 2006).
In vitro non-clinical studies
During the last years many changes have occurred 
not only in the cosmetic legislation but also in the chemical 
legislation of the European Union (REACH, “Registration, 
Evaluation, Authorization and Restriction of Chemicals”). 
The concept of the 3Rs appeared with the publication of 
“The Principles of Humane Experimental Technique” 
in 1959 by William Russell & Rex Burch, which refers 
to the refinement, reduction and substitution of the tests 
performed in animals (Cazarin, Corrêa, Zambrone, 
2004; Zuang, 2011). In 1978, David Smyth presented 
the definition of the 3Rs concerning the alternative 
experimentation, which includes all procedures that can 
completely replace the use of animals in experiments, that 
reduce the number of animals required, or that reduce the 
pain and suffering of these animals. However, it was only 
during the 70s and 80s that the international laws were 
changed and redefined based on the 3Rs concept. In 1993, 
one year after the creation of the European Centre for the 
Validation of Alternative Methods (ECVAM), with the 1st 
World Congress on the Use of Animals and Alternative 
Methods in Science, the worldwide movement based on 
the 3R’s really started.
During the past 25 years the most important step 
taken was the establishment of ECVAM and then the 
creation of the American equivalent ICCVAM in 1997. 
Soon after, in 2003, the 7th Amendment of the European 
Cosmetics Directive was established. This amendment 
establishes a prohibition of animal testing in finished 
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cosmetic products and cosmetic ingredients (“Testing 
Ban”). It also establishes a prohibition for marketing 
finished cosmetic products and ingredients included in 
cosmetic products, which have been tested on animals 
in the European community (“Marketing Ban”). The 
“Testing Ban” on finished cosmetic products has already 
been applied since September 11th, 2004 in the European 
Union countries. The “Testing Ban” on the ingredients 
or combination of ingredients has been progressively 
applied, concomitantly with the validation and adoption 
of alternative methods, but with a deadline of 6 years after 
2003, i.e. March 11th, 2009. The “Marketing Ban” will be 
progressively applied when the alternative methods are 
viable and adopted by the European legislation with the 
right consideration by the process of the OECD validation. 
This “Marketing Ban” was introduced on March 11th, 
2009 for all the human adverse effects studies, except for 
toxicokinetics, repeated dose and reproductive toxicity 
studies. For these specific studies a deadline of 10 years 
was defined after the entry of the 7th Amendment to start 
the “Marketing Ban”, i.e. March 11th, 2013, regardless the 
viability or not of the alternative methods.
All these changes indicate that the responsibility for 
the safety of cosmetics - and their ingredients - brought 
to the European market is placed on the manufacturer, 
first European importer or the trader of these products. 
This means that since March 2013, the cosmetics safety 
evaluation will only be possible in Europe by using 
validated in vitro models. That is, only alternative methods 
fully replacing the assays performed on animals have been 
accepted, eliminating all the tests performed on animals 
for the non-clinical evaluation of cosmetic ingredients 
and products. Other methods that were claimed to be 
alternative and that refined or reduced the use of animals 
are not accepted since 2013.
A retrospective validation study on four organotypic 
assays, i.e. the Bovine Corneal Opacity & Permeability 
test (BCOP), the Isolated Chicken Eye test (ICE), 
the Isolated Rabbit Eye test (IRE) and the Hen’s Egg 
Test on the Chorioallantoic Membrane (HET-CAM), 
was conducted between 2003 and 2006 by ICCVAM-
NICEATM, with ECVAM collaboration, to assess the 
ability of these assays for detecting severe eye irritants 
and ocular corrosives. After peer review, two assays, the 
BCOP and ICE tests, were endorsed as scientifically valid 
to identify ocular corrosives and severe irritants in the 
US and EU (ICCVAM, 2006a). Test guidelines for these 
two test methods were adopted by OECD Council on 
7th September, 2009 as OECD Test Guidelines (TG) 437.
In Brazil, despite the constant effort for reducing and 
replacing the use of animals for safety studies, tests using 
animals are still accepted by ANVISA with no expected 
prohibition (ANVISA, 2003). The main ophthalmological 
safety tests recommended by ANVISA through the Safety 
Guide (2003) are:
-  HET-CAM (“Hen’s Egg Test-Chorioallantoic Mem-
brane”);
-  BCOP (“Bovine Cornea Opacity Permeability”).
HET-CAM Alternative method
The purpose of the assay is to assess the ocular 
irritation potential of a product (soluble, emulsion, gel 
and oil products) in the Chorioallantoic Membrane 
of embryonated chicken egg, on the tenth day of 
incubation. The assay is based on the observation of 
irritant effects (hyperemia, hemorrhage and coagulation) 
for 5 minutes after pure or diluted product application, in 
the chorioallantoic membrane. The method is practical, 
with high sensitivity and low cost, however, it is not 
effective with very viscous and adherent products, because 
it causes washing and removal procedures to be hard after 
20 seconds of application in the membrane (Liebsch, 
Spielmann, 2002; McNamee, 2011). This test has not been 
validated by the international validation centers and is 
being reviewed by ECVAM and ICCVAM to be validated 
and accepted by the regulatory agencies. However, it is 
well accepted for evaluating ocular irritation of chemicals 
substances by REACH.
BCOP Alternative method
The Bovine Corneal Opacity and Permeability 
(BCOP) test method was evaluated by the Interagency 
Coordinating Committee on the Validation of Alternative 
Methods (ICCVAM), in conjunction with the European 
Centre for the Validation of Alternative Methods 
(ECVAM) and the Japanese Center for the Validation of 
Alternative Methods (JaCVAM), in 2006 and 2010 (1)
(2). In the first evaluation, the BCOP test method was 
evaluated concerning its usefulness to identify chemicals 
(substances and mixtures) inducing serious eye damage 
(1). In the second evaluation, the BCOP test method was 
evaluated concerning its usefulness to identify chemicals 
(substances and mixtures) not classified for eye irritation 
or serious eye damage.
The aim of the assay is to quantitatively evaluate 
the irritant potential of a chemical substance after the 
application in the isolated bovine cornea. The assay is 
based on the measurement of the opacity and permeability 
of the bovine cornea after contact with the test product.
•	 Measurement of the opacity of the cornea - per-
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formed by using an opacimeter, device that deter-
mines the difference of transmission of the luminous 
flow in the cornea to be evaluated, setting a numeri-
cal value of opacity.
•	 Measurement of the permeability of the cornea - 
performed according to the contact time, by adding 
fluorescein and measuring the optical density at 
490 nm. A scale is then obtained by considering the 
observed phenomena.
The OECD TG437 (adopted in 2009 and updated 
in 2013) includes the recommended use and limitations 
of the BCOP test method based on its evaluations. The 
identified limitations for the BCOP test method are based 
on the high false positive rates for alcohols and ketones 
and the high false negative rates for solids observed in the 
validation database.
The test is a good alternative to the Draize method, 
since it is fast and has good prediction of the ocular 
irritation degree of a wide variety of substances (Price, 
Andrews, 1985; Gordon, Kelly, 1989; Van Goethem, 
2011), and it has already been validated by ECVAM and 
ICCVAM, reviewed by ESAC with the OECD number 
TG437. This test is known as an organotypic study - study 
that uses isolated animal organs.
The ability of the BCOP test method to identify 
all categories of ocular irritation potential, as defined 
by the EPA (Environmental Protection Agency), EU 
(European Union), and GHS (Globally Harmonized 
System) classification systems (EPA 2003a) (EU 2008) 
(UN 2009), was evaluated by ICCVAM (2010a). Based on 
the current BCOP validation database (n=211 substances), 
which was updated since the ICCVAM evaluation of 
the BCOP test method for identifying ocular corrosives 
and severe irritants (ICCVAM 2006b), the overall 
correct classification ranged from 49% (91/187) to 55% 
(102/187) when evaluating the entire database, depending 
on the hazard classification system used. Based on these 
performance statistics, the BCOP test method is not 
considered to be valid as a complete replacement for the in 
vivo rabbit eye test for identifying all categories of ocular 
irritation (i.e. EPA Category II, III, IV; GHS Category 2A, 
2B, Not Classified; EU Category 2, Not Classified). Test 
substances inducing serious eye damage are classified as 
UN GHS Category 1. Chemicals not classified for eye 
irritation or serious eye damage are defined as those that 
do not meet the requirements for classification as UN GHS 
Category 1 or 2 (2A or 2B), i.e. they are referred to as UN 
GHS No Category. The BCOP test method was chosen to 
be used within a testing strategy such as the Top-Down/
Bottom-Up approach suggested by Scott et al. (2010).
Top-down/bottom-up strategy
Scott et al. (2010) published the outcome of an 
ECVAM expert meeting, with the aim of identifying 
testing strategies for eye irritation. A hazard identification 
testing scheme was proposed using a bottom–up (starting 
with test methods able to accurately identify non-
irritants) or top–down (starting with test methods able 
to accurately identify severe irritants) progression of 
in vitro tests. As such, the approach intends to identify 
non-irritants and severe irritants, leaving all others 
to the (mild/moderate) irritant categories. Once the 
identification of non-irritancy to the eye through an in 
vitro methodology is today not yet possible, the practical 
value of the proposal is limited.
Cytotoxicity tests
Furthermore, the cytotoxicity tests by the assay 
methods of mitochondrial metabolic activity (MTT), 
neutral red (NRU) and Red Blood Cell System (RBC) are 
also accepted by ANVISA and can be an alternative to 
the Draize test (Bednarczuk et al., 2010); although these 
tests are not validated by ECVAM for ocular irritation 
assessment.
The cytotoxicity assay by the RBC method studies 
the effects of products and their ingredients isolated on 
the plasma membrane of red blood cells, analyzing the 
phenomena of hemolysis and denaturation of hemoglobin. 
The relation between the hemolysis and the hemoglobin 
oxidation provides a parameter to characterize the in 
vitro effects of these substances (Wolfgan, Pfnnenbecker, 
Hoppe, 1987). This method, however, was not approved 
in the validation process of ECVAM and ICCVAM.
The MTT measures the mitochondrial activity of 
the viable cells in metabolizing the tetrazolium salts, by 
using cell cultures with MTT vital colorant. The evaluation 
final parameter is to establish the IC50 (the concentration 
of test substance that inhibits 50% of cell growth). It is 
not applicable to products that are not soluble in water 
or ethanol and or DMSO (Abreu, 2008). This end-point 
is applied for evaluating skin irritation in 3D models 
of epidermis that is equivalent to the one that has been 
validated and has the OECD number 439. It is necessary to 
check the method for possible direct MTT reduction with 
test substances. This verification should be done before 
starting the experiments.
Finally, as in the cytotoxicity method with MTT, 
the cytotoxicity method with neutral red (NRU) uses cell 
culture with a vital colorant, the NR, or the neutral red 
colorant. The method measures the retention activity of 
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the colorant by the lysosomes of the viable cells and is 
described at ISO 10.993-5. The evaluation final parameter 
is also the establishment of IC50. This method cannot be 
used for studying substances that have fixing properties 
(Tani et al., 1999). This method has been validated to 
reduce the number of animals used for evaluating the 
Acute Oral Toxicity of chemical substances, and it is 
described in OECD TG129.
Following the study of irritation potential of raw 
materials in non-clinical assays, the finished product goes 
to the second phase of safety tests, to be performed in 
human subjects. The clinical studies are required because 
many times the response to certain substances in humans 
can be different when compared with the responses 
observed in animals - situation called idiosyncrasy. These 
tests are usually outsourced by the cosmetic industries. In 
Brazil, there are several research institutes that provide 
such services, which must be qualified by ANVISA or 
INMETRO (Raymundo, Goldim, 2002).
Processes of in vitro method validation
Validated alternative methods are those which 
relevance (scientific basis and predictive ability of the test 
system) and reproducibility (reproducibility of test results 
obtained within a laboratory and among laboratories) have 
been established for a particular purpose. An alternative 
method for the replacement of a test conducted on animals 
is a combination of a test system, and a prediction model. 
The test system generates a number of physico-chemical 
data or in vitro data for the chemical substance of interest. 
The prediction model or data interpretation procedure is 
an unambiguous algorithm to convert these data to predict 
in vivo toxicology results, called in animals or humans.
The criteria and procedures for validating methods 
have been developed and implemented in Europe by 
the ECVAM - European Centre for the Validation of 
Alternative Methods and its independent Committee 
ESAC - European Scientific Advisory Committee, in the 
United States by the ICCVAM - Interagency Coordinating 
Committee on the Validation of Alternative Methods, 
in Japan by the JaCVAM - Japanese Centre for the 
Validation of Alternative Methods and internationally by 
the OECD - Organization for Economic Co-Operation 
and Development.
The main objective of this validation body is to 
promote the scientific and regulatory acceptance of 
alternative methods through research, development 
and validation of new tests, aiming to contribute for 
the principle of the 3Rs (Reduction, Refinement and 
Replacement of animal tests).
Before an alternative method is officially accepted 
by the regulatory agencies, it is essential that the validity 
of the new methods be demonstrated in an independent 
validation and scientifically accurate program. However, 
until 1990 there was no scientific approach on the subject 
or a guide of the regulatory agencies for the experimental 
validation of in vitro toxicity tests. During the second 
validation workshop, held in Amden in 1994 and chaired 
by ECVAM, essential elements for the validation process 
were defined. In 1995/96 the validation procedure of 
ECVAM was officially accepted by the member-countries 
of the European Union and by the international official 
agencies such as the American agencies and the OECD. 
The concept of validation was immediately installed and, 
in 1998, the NRU 3T3 phototoxicity in vitro test was the 
first experiment successfully validated using this concept. 
Today there are several other valid and in process of 
validation methods and a few that have been validated 
and approved by international regulatory agencies (Eskes 
et al., 2005).
The ECVAM is the international reference center 
for the development and validation of alternative methods 
directed for replacement, reduction and refinement of 
animal use in biomedical science, with emphasis on the 
toxicological evaluation. This center was founded by the 
European Commission in 1992 to achieve the objectives 
of Directive 86/609/EC about the protection of animals 
used for experimental and other scientific proposals (Eskes 
et al., 2005).
According to ECVAM, validation is the process 
by which trust and relevance of the procedure are 
established for a particular purpose (Balls et al., 2006). 
And validated methods are those that comply with the 
validation process adopted in the European Union by 
ECVAM and its Committee of Independent Consultants 
ESAC. During the pre-validation process, the method 
must first become valid. Since the alternative method went 
through the process of pre-validation and validation, it 
will be analyzed by the SCCP (Scientific Committee on 
Consumer Products). After approval by the SCCP, it will 
be submitted for approval by the regulatory agencies and 
written OECD guideline. That being said, it is clear that the 
process of validation of any alternative method for safety 
evaluation of chemical substances and finished products in 
Brazil is a factor of scientific, technological and industrial 
development and competitiveness for the cosmetic, 
sanitizing, pesticides and pharmaceutical industry.
Clinical studies
Since the cosmetic products are produced with raw 
Safety assessment of cosmetic products, with emphasis on the ocular area 673
materials known to be safe, as per the lists of ingredients 
made available by the Regulatory Agency and found in 
the literature, and that new raw materials are incorporated 
in these products only after they have been extensively 
studied through pre-clinical tests, the clinical studies aim 
to prove the safety of these products in humans. These 
studies allow knowing the action of the product, directly 
into the target public, on the mucosa or on the skin from 
different body areas.
Tests conducted with humans are governed by very 
strict laws in order to protect and safeguard people. These 
laws vary from country to country. In Brazil, these studies 
are allowed, provided that they comply with the precepts 
of the Helsinki Declaration and the CNS 196/96 (RDC 
196, 1987). In addition, the product evaluation in humans 
must follow the Good Clinical Practices (GCP), for the 
welfare of the study subject and evaluation of the benefit-
risk relation associated with the study.
There are different studies for evaluating the ocular 
irritation potential of cosmetic products in humans. 
Some studies are performed under controlled and 
maximized conditions (Ocular instillation study), while 
others evaluate the product under real use conditions 
(Ophthalmological Acceptance studies).
Before testing a cosmetic product in the ocular area - 
which is a mucous tissue area, highly sensitive and of high 
permeation - it is important to know and prove its safety 
through compatibility clinical studies. In compatibility 
studies, the products are tested under occlusive or semi-
occlusive maximized condition, by using adhesives (patch 
tests) attached to the back or forearm of the study subject, 
with the objective of proving the absence of irritant or 
allergenic potential.
Next, the Ocular Irritation studies are suggested. 
The most appropriate type of study, Ocular instillation or 
Ophthalmological Acceptance, is determined according 
to the product category. The Ocular Instillation test 
is recommended for rinse-off products for children, 
such as shampoos, conditioners and liquid soaps/body 
washes. These are products that, during use, may have 
direct contact with the children’s ocular mucosa. It 
is suitable for children’s products, because they are 
products that have lighter formulations with lower 
concentrations of surfactants. Through this test, it is 
possible to explore claims such as “Tear-free” and “No 
Tears”. The Ophthalmological Acceptance studies are 
recommended for products to be used on the face or on 
the periocular area, such as makeup (eyeliner, eye pencil, 
mascara) and facial or eye-area creams. In this case, the 
most suitable exposure is under real use conditions for 
evaluating safety.
The Ocular irritation test by instillation consists in 
applying the product - diluted in physiological solution 
at predetermined concentrations –directly to the subjects’ 
eyes. In these studies, the subjects are initially assessed by 
an Ophthalmologist using a slit lamp, for checking their 
eligibility. This selection is made by following specific 
exclusion criteria, such as: conjunctival corneal conditions 
and periocular area conditions, use of contact lenses, 
pregnancy/lactation, and other diseases or medications 
that may directly interfere in the study or endanger the 
subject’s health.
The diluted product is then instilled into the 
conjunctival sac of one eye of the subjects while drops 
of physiological solution are instilled in the other eye, 
which will serve as a control. After instillation, subjects 
are assessed again by the ophthalmologist for assessing 
and rating ocular signs and symptoms, such as hyperemia 
and burning. New visits to the institute are held in order 
to assess possible adverse events that may arise later. The 
scores given by the ophthalmologist are used to calculate 
the degree of ocular irritation of the product.
Through this study the ophthalmologist is able to run 
a qualitative assessment of the increased tears caused by 
the product, allowing the evaluation and support of claims 
such as “Tear-free” and “No Tears”.
On the other hand, in Ocular Acceptance studies, 
the product is tested under real use conditions. That is, the 
study subject uses the product at home, according to the 
use directions specified by the manufacturer (ANVISA, 
2003).
In the acceptance studies, subjects are initially 
assessed by a physician. If approved, they are allowed to 
take the test product to be used at home - according to the 
use directions recommended by the manufacturer - and 
are examined again at the end of the study, usually after 3 
or 4 weeks of product use.
It is important to have such studies supervised 
by an ophthalmologist, since many ocular parameters 
are assessed. The external area of the eye is formed 
by the conjunctival membrane and by the cornea. The 
cornea is the most important external tissue formed by 
lamellar fibers parallel distributed, which gives it optical 
transparency. This is a tissue with several nerve endings, 
therefore extremely sensitive to pain. Its most external 
layer, the epithelium, acts as a barrier to microorganisms’ 
entry. Therefore, any epithelial lesion of the cornea 
predisposes to an infection, which may cause corneal 
ulcer and a permanent lesion. Many studies consider the 
use of fluorescein - a commercial eye drop widely used in 
ophthalmological clinical centers - because its coloring 
action allows evaluating corneal lesions, if any.
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These studies are important because they allow 
evaluating the product under real use conditions, in 
which specific characteristics of the product or of its use 
directions can be identified and then taken into account 
for developing the content of the product label. Therefore, 
they represent a more appropriate evaluation of products 
applied close to the eyes, because they allow identifying 
responses under predictable use conditions and also under 
inappropriate/incorrect use conditions. This allows the 
manufacturer to have more information and thus more 
technical background to define the use directions of the 
product, as well as the use precautions.
The number of subjects required for a study varies 
according to specific protocols of the study centers and 
according to the recommendation of the Guide for the 
Safety Evaluation of Cosmetic Products of ANVISA. 
The Acceptance studies, for example, must be completed 
with a minimum number of 30 responses, as mentioned 
in the Safety Guide of ANVISA. The Irritation studies 
by instillation - as they occur under maximized and very 
controlled conditions may be completed with a smaller 
number of responses.
CONCLUDING REMARKS
The safety support of a cosmetic product is very 
important, taking into account that the consumer has free 
access to these products of widespread use in today’s 
society. Every year, new products for eyes are launched, 
such as makeup items and face creams, and therefore the 
number of consumers has increased considerably.
Proving that products applied too close to the eyes 
are safe – by evaluating their ocular irritation potential 
– is very important because direct contact with the eyes 
may occur in several situations: incorrect application of 
product, sweating or even skin scratching.
The  concern  wi th  r igorous  and  e ffec t ive 
oph tha lmolog ica l  s tud ies  i s  e ssen t ia l  so  tha t 
ophthalmologically safe products are launched on the 
market.
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